Akebia Ther Market Cap ($186.10 Million)
Market Cap & Net Worth: Akebia Ther (AKBA)
Akebia Ther market cap. Akebia Ther (NASDAQ:AKBA) has a market capitalization of $186.10 Million ($186.10 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16628 globally and #3963 in its home market, demonstrating a 5.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akebia Ther's stock price $0.69 by its total outstanding shares 267879239 (267.88 Million). Also see Akebia Ther cash conversion from operations for how efficiently the company converts equity into cash flow.
Akebia Ther Market Cap History (2015–2026)
Akebia Ther market cap history from 2015 to 2026. Data shows change from $3.46 Billion to $186.10 Million (-22.09% CAGR). Check Akebia Ther (AKBA) share price today for real-time trading data and today's change.
Index Memberships
Akebia Ther is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #452 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1637 of 3165 |
Weight: Akebia Ther's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Akebia Ther Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akebia Ther's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AKBA year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.83x
Akebia Ther's market cap is 1.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.79 Billion | $1.53 Million | -$135.75 Million | 1816.69x | N/A |
| 2017 | $3.98 Billion | $177.98 Million | -$76.91 Million | 22.38x | N/A |
| 2018 | $1.48 Billion | $207.74 Million | -$171.90 Million | 7.13x | N/A |
| 2019 | $1.69 Billion | $335.00 Million | -$279.66 Million | 5.05x | N/A |
| 2020 | $750.06 Million | $295.31 Million | -$349.87 Million | 2.54x | N/A |
| 2021 | $605.41 Million | $213.58 Million | -$244.87 Million | 2.83x | N/A |
| 2022 | $154.57 Million | $292.48 Million | -$94.23 Million | 0.53x | N/A |
| 2023 | $332.17 Million | $194.62 Million | -$51.92 Million | 1.71x | N/A |
| 2024 | $508.97 Million | $160.18 Million | -$69.41 Million | 3.18x | N/A |
| 2025 | $431.29 Million | $236.20 Million | -$5.34 Million | 1.83x | N/A |
Competitor Companies of AKBA by Market Capitalization
Companies near Akebia Ther in the global market cap rankings as of November 5, 2026. Also see AKBA total asset value for a full breakdown of the balance sheet.
Key companies related to Akebia Ther by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Akebia Ther (2015–2026)
Market capitalization of Akebia Ther from 2015 to today. Between 2015 and today, Akebia Ther's market cap moved from $3.46 Billion to $ 186.10 Million, with a yearly change of -22.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $186.10 Million | -56.85% |
| 2025 | $431.29 Million | -15.26% |
| 2024 | $508.97 Million | +53.23% |
| 2023 | $332.17 Million | +114.90% |
| 2022 | $154.57 Million | -74.47% |
| 2021 | $605.41 Million | -19.29% |
| 2020 | $750.06 Million | -55.70% |
| 2019 | $1.69 Billion | +14.29% |
| 2018 | $1.48 Billion | -62.81% |
| 2017 | $3.98 Billion | +42.84% |
| 2016 | $2.79 Billion | -19.43% |
| 2015 | $3.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Akebia Ther was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $186.10 Million USD |
| MoneyControl | $186.10 Million USD |
| MarketWatch | $186.10 Million USD |
| marketcap.company | $186.10 Million USD |
| Reuters | $186.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more